Basilea Pharmaceutica AG investor relations material

Basilea Pharmaceutica Ltd. operates as a commercial stage biopharmaceutical company in the United States and internationally. The company focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives, and various supportive care products for cancer patients undergoing chemotherapy treatment or for those being treated with antibiotics. It also develops ceragenin technology to treat hospital acquired bacterial infections; and CRAPOMICIN, a novel, semi-synthetic lipoglycopeptide antibiotic candidate, which is in clinical development for complicated skin and soft tissue infections, including acute bacterial skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus bacteria, as well as ventilator associated pneumonia caused by Gram negative bacteria.